163217-67-2

Usage

Uses

Used in Pharmaceutical Industry:
2-[2-(4-Fluorophenyl)-2-oxo-1-phenyl-ethyl]-4-methyl-3-oxo-pentanoic Acid, (4-Benzyloxy-phenyl)-amide is used as an intermediate in the synthesis of Atorvastin for the treatment of hypercholesterolemia. Atorvastin is a selective, competitive HMG-CoA reductase inhibitor, specifically indicated for lowering both elevated LDL-cholesterol and triglycerides in patients with hypercholesterolemia.
Used in Cardiovascular Applications:
In the field of cardiovascular health, 2-[2-(4-Fluorophenyl)-2-oxo-1-phenyl-ethyl]-4-methyl-3-oxo-pentanoic Acid, (4-Benzyloxy-phenyl)-amide contributes to the development of Atorvastin, which is essential in managing and reducing the risk of cardiovascular diseases associated with high cholesterol levels. By lowering LDL-cholesterol and triglycerides, Atorvastin helps in preventing the formation of plaques in the arteries, thus reducing the risk of heart attacks and strokes.
Used in Research and Development:
2-[2-(4-Fluorophenyl)-2-oxo-1-phenyl-ethyl]-4-methyl-3-oxo-pentanoic Acid, (4-Benzyloxy-phenyl)-amide is also utilized in research and development for the study of HMG-CoA reductase inhibitors and their potential applications in treating other related conditions. The understanding of its chemical properties and interactions with other molecules can lead to the discovery of new drugs and therapies for various health issues.

Upstream product

• 100-52-7 benzaldehyde 
• 42558-54-3 Methyl 4-methyl-3-oxopentanoate 
• 54016-70-5 3-ethyl-5-(2-hydroxyethyl)-4-methyl-1,3-thiazolium bromide 
• 265989-30-8 N-(4-(benzyloxy)phenyl)-4-methyl-3-oxopentanamide 
• 459-57-4 4-fluorobenzaldehyde 
• 163217-66-1 2-benzylidene-N-(4-(benzyloxy)phenyl)-4-methyl-3-oxopentanamide 

Downstream Products

• 265989-36-4 tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-4-((4-hydroxyphenyl)carbamoyl)-5-isopropyl-3-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate 
• 163217-70-7 p-Hydroxyatorvastatin lactone 
• 214217-88-6 p-Hydroxyatorvastatin 
• 163217-68-3 tert-butyl 2-((4R,6R)-6-(2-(3-((4-(benzyloxy)phenyl)carbamoyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate 

Relevant academic research and scientific papers

Atorvastatin Derived HMG-CoA Reductase Degradation Inducing Compound

The present invention relates to a HMG-CoA reductase degradation-inducing compound and, more specifically, to a bifunctional compound in which atorvastatin and E3 ubiquitin ligase binding moiety are chemically linked as HMG-CoA reductase binding moiety, to a production method thereof, to a HMG-CoA reductase degradation method using the same, and to a pharmaceutical composition for preventing or treating HMG-CoA reductase-related diseases, comprising the same.

PYRROLE COMPOUNDS AND USES THEREOF

Pyrrole compounds, compositions and methods are provided for the treatment, prevention, or amelioration of neurodegenerative diseases, cardiovascular diseases, proliferative diseases and visual disorders. In particular, pyrrole compounds, compositions and methods for the treatment of stroke are disclosed herein.

Synthesis of deuterium-labeled atorvastatin and its metabolites for use as internal standards in a LC/MS/MS method developed for quantitation of the drug and its metabolites in human serum

D5-labeled isotopomers of atorvastatin, atorvastatin lactone and its hydroxy metabolites were synthesized as internal standards for use in a LC/MS/MS method developed for the simultaneous quantitative determination of atorvastatin and its hydroxy metabolites in human serum. d5-Atorvastatin and d5-atorvastatin lactone were prepared from d5-aniline whereas their corresponding hydroxy metabolites were synthesized using d5-benzaldehyde.

[(Hydroxyphenylamino) carbonyl] pyrroles

2-(4-Fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(hydroxyphenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, and their lactone forms, and salts and solyates thereof, inhibit cholesterol biosynthesis, and thus are useful in treating hyperchole